Advertisement

Comment on: “the FDG PET/CT score” for the diagnosis of malignant pleural effusion

  • Dharmender MalikEmail author
Letter to the Editor
  • 70 Downloads
Part of the following topical collections:
  1. Oncology – Chest

Dear Sir,

Pleural effusion, caused by a number of malignant and benign diseases, is a common and challenging medical problem. Malignant pleural effusion (MPE) is frequently observed in multiple malignancies, with lung cancer being the most frequent underlying malignancy [1, 2]. The diagnosis of malignant pleural effusion adversely affects a patient’s staging and prognosis and may alter the therapeutic approach [3]. Computed tomography (CT) and positron emission tomography (PET) as non-invasive methods have been used to characterize pleural effusion as malignant or benign and can trigger the determination of etiology in some cases [4]. Meta-analysis by Porcel et al. had predicted the pooled sensitivity, specificity, and positive likelihood ratio of 81%, 74%, and 3.22 respectively with area under the curve of 0.838 for identifying malignant effusion using semiquantitative interpretation of integrated PET-CT imaging system [5]. However, none of the imaging measurements appear to predict...

Notes

Compliance with ethical standards

Conflict of interest

No conflict of interest to declare.

Statement of informed consent

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346:1971–7.  https://doi.org/10.1056/NEJMcp010731.CrossRefPubMedGoogle Scholar
  2. 2.
    Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. BTS pleural disease guideline group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii32–40.  https://doi.org/10.1136/thx.2010.136994.CrossRefPubMedGoogle Scholar
  3. 3.
    Nakajima R, Abe K, Sakai S. Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore). 2015 Jul;94(29):e1010.  https://doi.org/10.1097/MD.0000000000001010.CrossRefGoogle Scholar
  4. 4.
    Sun Y, Yu H, Ma J, Lu P. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764.  https://doi.org/10.1371/journal.pone.0161764.eCollection2016.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Porcel JM, Hernandez P, Martinez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147:502–12.  https://doi.org/10.1378/chest.14-0820.CrossRefPubMedGoogle Scholar
  6. 6.
    Yang M-F, Tong Z-H, Wang Z, Zhang Y-Z, Xu L-L, Wang X-J, et al. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion. Eur J Nucl Med Mol Imaging. 2019;46(7):1457–67.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and PET/CT, Centre for Advanced Research in imaging, Neuroscience and Genomics (CARING)Sir Ganga Ram HospitalNew DelhiIndia

Personalised recommendations